Forecasting cytokine storms with new predictive biomarkers

Rayne H. Rouce, Helen Heslop

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


T cells genetically modified with CD19 chimeric antigen receptors have produced impressive clinical responses in patients with refractory B-cell malignancies, but therapeutic responses are often accompanied by cytokine release syndrome (CRS), which can cause significant morbidity and mortality. Teachey and colleagues have identified predictive biomarkers for this complication that may allow testing of earlier intervention with agents such as the IL6 receptor blocker tocilizumab to evaluate whether CRS can be ameliorated without jeopardizing clinical responses.

Original languageEnglish (US)
Pages (from-to)579-580
Number of pages2
JournalCancer Discovery
Issue number6
StatePublished - Jun 2016

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Forecasting cytokine storms with new predictive biomarkers'. Together they form a unique fingerprint.

Cite this